Clinical Trial Update: A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults. [Phase 3]

View source ↗

Summary

Pfizer reported results from a Phase 3 study evaluating the safety, tolerability and immunogenicity of RSVpreF delivered in multidose vials in healthy female ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSVpreF

Snippet

Sponsor: Pfizer | Conditions: Respiratory Syncytial Virus (RSV) | Phase 3 | Status: COMPLETED | Results posted: 2025-09-25